全球標靶癌症治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球標靶癌症治療市場預計將從2025年的985.8億美元成長至2034年的1,804.7億美元，2026年至2034年的複合年成長率（CAGR）為6.95%。該市場快速成長的原因在於精準醫療方法在癌症治療的應用日益廣泛。標靶癌症治療旨在針對與癌症進展相關的特定分子通道或基因異常，與傳統療法相比，可提高治療效果並減少副作用。癌症發生率的上升、基因組學研究的進展以及人們對個人化醫療方案日益成長的認知，都推動了市場的擴張。醫療服務提供者正擴大利用標靶治療來改善患者的治療效果。

分子診斷、生物標記識別和藥物研發領域的持續創新正推動著這個市場的發展。製藥公司正大力投資於旨在開發針對特定癌症突變和訊號路徑療法的研究計畫。不斷擴大的臨床試驗活動和監管部門對精準腫瘤學的支持，正在創造巨大的成長機會。此外，伴隨診斷技術的進步也使得患者篩選和治療方案製定更加精準。

癌症治療前景依然十分光明，基因體學和生物技術的進步不斷革新著這一領域。新型分子通道和針對罕見癌症類型的新療法的出現，有望進一步拓展治療選擇。人工智慧（AI）與基因組分析的融合，可望進一步加強藥物研發和個人化治療策略。隨著醫療系統日益重視精準醫療，癌症標靶治療市場預計將在長期內保持持續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含多個關鍵組成部分，旨在幫助您全面了解市場環境。

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的關鍵促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。本部分深入分析了競爭趨勢以及主要參與者所採取的策略，提供了寶貴的見解。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新的投資機會。本部分重點在於潛在的成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，可根據客戶需求進行調整。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更有效地支援策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球標靶癌症治療市場：依治療類型分類

• 市場分析、洞察與預測
• 小分子藥物
• 單株抗體
• 免疫療法
• 其他

第5章 全球標靶癌症治療市場：依癌症類型分類

• 市場分析、洞察與預測
• 肺癌
• 乳癌
• 結腸癌
• 血癌
• 婦科癌症
• 其他

第6章 全球標靶癌症治療市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 癌症及放射治療中心
• 專科診所

第7章 全球標靶癌症治療市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和分銷通路合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Amgen Inc
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co.Inc
  • Novartis AG
  • Pfizer Inc
  • Eli Lilly And Company
  • Sanofi SA

The global targeted cancer therapy market size is expected to reach USD 180.47 Billion in 2034 from USD 98.58 Billion in 2025, growing at a CAGR of 6.95 during 2026-2034.This market is experiencing rapid growth due to increasing adoption of precision medicine approaches in oncology treatment. Targeted cancer therapies are designed to attack specific molecular pathways and genetic abnormalities associated with cancer progression, offering improved treatment effectiveness and reduced side effects compared to conventional therapies. Rising cancer prevalence, advances in genomic research, and growing awareness of personalized treatment options are supporting market expansion. Healthcare providers are increasingly utilizing targeted therapies to improve patient outcomes.

The market is benefiting from continuous innovation in molecular diagnostics, biomarker identification, and drug development. Pharmaceutical companies are investing heavily in research programs aimed at developing therapies that address specific cancer mutations and signaling pathways. Expanding clinical trial activity and regulatory support for precision oncology are creating significant growth opportunities. Additionally, improvements in companion diagnostic technologies are enabling more accurate patient selection and treatment planning.

Future prospects remain exceptionally strong as advances in genomics and biotechnology continue transforming cancer care. Emerging therapies targeting novel molecular pathways and rare cancer types are expected to broaden treatment options. Increasing integration of artificial intelligence and genomic analytics will further enhance drug discovery and personalized treatment strategies. As healthcare systems emphasize precision medicine, the targeted cancer therapy market is projected to experience sustained long-term growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy Type

• Small Molecule Drugs
• Monoclonal Antibodies
• Immunotherapies
• Others

By Cancer Type

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Blood Cancer
• Gynecologic Cancer
• Others

By End User

• Hospitals
• Cancer and Radiation Therapy Centers
• Specialty Clinics

COMPANIES PROFILED

• Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Sanofi S.A.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TARGETED CANCER THERAPY MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. Small Molecule Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Immunotherapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TARGETED CANCER THERAPY MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Blood Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Gynecologic Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TARGETED CANCER THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer and Radiation Therapy Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL TARGETED CANCER THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy Type
  • 7.2.2 By Cancer Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy Type
  • 7.3.2 By Cancer Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy Type
  • 7.4.2 By Cancer Type
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy Type
  • 7.5.2 By Cancer Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy Type
  • 7.6.2 By Cancer Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL TARGETED CANCER THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Amgen Inc
  • 9.2.2 AstraZeneca Plc
  • 9.2.3 Bayer AG
  • 9.2.4 Bristol-Myers Squibb Company
  • 9.2.5 F. Hoffmann-La Roche Ltd
  • 9.2.6 GlaxoSmithKline Plc
  • 9.2.7 Johnson & Johnson
  • 9.2.8 Merck & Co.Inc
  • 9.2.9 Novartis AG
  • 9.2.10 Pfizer Inc
  • 9.2.11 Eli Lilly And Company
  • 9.2.12 Sanofi S.A